Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure

BACKGROUND: Anthracyclines are widely used in the treatment of childhood cancer. One of the well-recognized side-effects of anthracycline therapy is dose-dependent cardiomyopathy that may progress to heart failure (HF) years after completion of cancer-directed therapy. This study will evaluate the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Armenian, Saro H., Hudson, Melissa M., Chen, Ming Hui, Colan, Steven D., Lindenfeld, Lanie, Mills, George, Siyahian, Aida, Gelehrter, Sarah, Dang, Ha, Hein, Wendy, Green, Daniel M., Robison, Leslie L., Wong, F. Lennie, Douglas, Pamela S., Bhatia, Smita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050602/
https://www.ncbi.nlm.nih.gov/pubmed/27716152
http://dx.doi.org/10.1186/s12872-016-0364-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050602/
https://www.ncbi.nlm.nih.gov/pubmed/27716152
http://dx.doi.org/10.1186/s12872-016-0364-6

Ejemplares similares